SLDB · Solid Biosciences Inc.

Summary

Solid Biosciences Inc. entered into a securities purchase agreement for a private placement of 14,973,257 shares of common stock at $5.61 per share and pre-funded warrants to purchase 27,807,482 shares at $5.609 per warrant, expecting gross proceeds of $240.0 million and net proceeds of $226.8 million. The net proceeds, combined with existing cash of approximately $187.9 million as of December 31, 2025, are estimated to fund operations into the first half of 2028.

Key takeaways

• Private placement of 14,973,257 common shares at $5.61/share and pre-funded warrants for 27,807,482 shares at $5.609/warrant
• Expected gross proceeds $240.0 million, net proceeds $226.8 million after fees
• Closing expected on or about March 9, 2026
• Preliminary cash, cash equivalents and available-for-sale securities of $187.9 million as of Dec 31, 2025
• Combined cash runway extends into first half of 2028
• Investors include Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, Deep Track Capital